Oncology
and Radiotherapy©
18(6) 2024: 001-004 • CASE SERIES

Modelling the effect of Docosa Hexaenoic Acid (DHA) in cancer therapy

Satyanararayana Rentala[1,2], Mounika Ramachandruni[1], Varsha Hannah George[1], Aditi Jha[1], Shaik Gulnaz[2], Saradha Janaki Gundlapalli[1]

[1] Department of Genetics and Molecular Biology, School of Health Science, The Apollo University, Chittoor, Andhra Pradesh, India
[2] Department of Biomedical Science, School of Health Science, The Apollo University, Chittoor, Andhra Pradesh, India

ABSTRACT

Background: Docosahexaenoic Acid (DHA), an omega-3 fatty acid, has demonstrated potential anti-cancer properties, including anti-proliferative and pro-apoptotic effects on tumor cells. Understanding the impact of DHA on tumor growth dynamics can inform therapeutic strategies and optimize treatment efficacy. Tumor growth models, including the exponential, logistic, and Gompertz models, provide frameworks for quantifying these effects.

Objective: This study aims to integrate the effects of DHA into various tumor growth models to evaluate its impact on tumor dynamics and to provide insights into its potential as a therapeutic agent in cancer treatment.

Methods: The effects of DHA were incorporated into the exponential, logistic, and Gompertz growth models by modifying the intrinsic growth rate parameter. Experimental data from in vitro and in vivo studies were used to estimate the reduction in growth rates due to DHA treatment. The modified models were analyzed to determine the extent of DHA's impact on tumor growth.

Results: Incorporation of DHA into the exponential growth model indicated a significant reduction in the intrinsic growth rate (*rr*), reflecting its inhibitory effect on tumor proliferation. The logistic growth model, which accounts for environmental carrying capacity, showed that DHA not only reduced the growth rate but also potentially affected the carrying capacity (*K*K), suggesting an influence on the tumor microenvironment. The Gompertz model, suitable for long-term growth dynamics, demonstrated that DHA decreased the initial growth rate and might affect the deceleration parameter (*b*b), indicating sustained inhibition of tumor growth over time.

Conclusion: Integrating DHA into tumor growth models provides a quantitative understanding of its anti-tumor effects. DHA effectively reduces tumor growth rates across different models, highlighting its potential as a valuable component of cancer therapy. Further research should focus on optimizing DHA dosage and administration schedules, exploring its synergistic effects with other treatments, and validating these findings in clinical settings.

Keywords: Docosa Hexaenoic Acid (DHA), tumor growth models, exponential model, logistic model, Gompertz model, cancer therapy, growth rate reduction

Address for correspondence:

Satyanararayana Rentala,

Department of Biomedical Science, School of Health Science, The Apollo University, Chittoor, Andhra Pradesh, India

E-mail: profsr@apollouniversity.edu.in

Word count: 3771 **Tables:** 00 **Figures:** 01 **References:** 13

Received: 15 May, 2024, Manuscript No. OAR-24-134997

Editor Assigned: 30 May, 2024, Pre-QC No. OAR-24-134997(PQ)

Reviewed: 05 June, 2024, QC No. OAR-24-134997(Q)

Revised: 10 June, 2024, Manuscript No. OAR-24-134997(R)

Published: 17 June, 2024, Invoice No. J-134997

INTRODUCTION

Tumor growth models are mathematical and computational frameworks used to describe and predict the dynamics of tumor development and progression. These models are critical for understanding cancer biology, planning treatment strategies, and designing clinical trials [1, 2]. They range from simple models describing overall tumor growth to complex models incorporating various biological processes and interactions [3, 4].

Tumor growth models are mathematical representations that describe the dynamics of tumor development and progression [5, 6]. These models are essential in understanding tumor biology, predicting treatment outcomes, and optimizing therapeutic strategies [7-13].

In this paper the authors are presenting the mathematical models for tumor growth and the incorporation of Docosa Hexaenoic Acid (DHA) in Tumor Growth Models:

Types of tumor growth models

There are numerous tumor growth models, each with its own strengths and limitations.

Empirical models:

- Exponential growth model: Assumes that tumor cells grow at a constant rate. Simple but often unrealistic, as it doesn't account for factors like nutrient depletion.

$$N(t) = N_0 e^{rt}$$

Where N(t) is the tumor size at time t, N_0 is the initial tumor size, and r is the growth rate.

- Logistic growth model: Incorporates a carrying capacity, representing the maximum tumor size that the environment can support.

$$N(t) = \frac{N_0 K e^{rt}}{K + N_0(e^{rt} - 1)}$$

Where *K* is the carrying capacity

Gompertz model:

Describes tumor growth slowing down exponentially as the tumor size increases.

$$N(t) = N_0 e^{\frac{r}{k}(1-e^{-kt})}$$

where κ is a Deceleration parameter

Mechanistic models:

- Cellular automaton models: Use a grid where each cell follows simple rules based on the state of neighboring cells, allowing simulation of complex behaviors from simple local interactions.
- Agent-Based Models (ABM): Simulate the actions and interactions of individual cells to assess their effects on the system as a whole. These models are useful for studying heterogeneous tumor environments and treatment responses.
- Continuous models: Use Partial Differential Equations (PDEs) to describe changes in tumor cell density over time and space, considering factors like nutrient diffusion and cell motility.

Hybrid models:

- Combine elements of discrete (e.g., cellular automaton) and continuous (e.g., PDE) approaches to capture both individual cell behaviors and population-level dynamics (Figure 1).



Fig. 1. Tumor Growth Models: Panel A) represents the tumor growth and the microenvironment leading to the growth of the tumor; Panel B) represents application of mathematical models for the study of tumor growth

Key components in tumor growth models

- Tumor microenvironment: Includes interactions with the extracellular matrix, blood vessels, and immune cells.
- Angiogenesis: The process of new blood vessel formation to supply nutrients to the tumor.
- Metastasis: The spread of cancer cells from the primary tumor to distant sites.
- Therapy response: Modeling the effects of chemotherapy, radiotherapy, immunotherapy, and targeted therapies on tumor growth and resistance development.

Applications

- Predicting tumor growth: Estimating tumor size over time to aid in clinical decision-making.
- Optimizing treatment: Designing and optimizing treatment schedules to maximize efficacy and minimize side effects.
- Understanding mechanisms: Gaining insights into the biological processes underlying tumor growth and response to treatment.
- Clinical trials: Simulating clinical trial outcomes to improve design and interpretation.

Challenges and future directions

- Parameter estimation: Determining accurate model parameters from experimental and clinical data.
- Heterogeneity: Accounting for genetic, phenotypic, and environmental heterogeneity within tumors.
- Validation: Ensuring model predictions are robust and match experimental or clinical observations.
- Computational complexity: Managing the computational demands of detailed mechanistic and hybrid models.

Incorporating Docosa Hexaenoic Acid (DHA) in tumor growth models

Docosa Hexaenoic Acid (DHA), an omega-3 fatty acid, has been extensively studied for its potential anti-cancer properties. Incorporating DHA into tumor growth models can help understand its effects on tumor dynamics and aid in developing effective therapeutic strategies. Here, we discuss various applications of DHA within different tumor growth models: exponential, logistic, and Gompertz.

Applications of DHA in tumor growth models

Exponential growth model:

The exponential growth model is described by:

$$N(t) = N_0 e^{rt}$$

Where (t) is the tumor size at time t, N_0 is the initial tumor size, and r is the intrinsic growth rate.

Application with DHA:

- Effect on growth rate: DHA can be modelled as reducing the growth rate r. Experimental studies can quantify the reduction (Δr) by comparing growth rates of tumors with and without DHA treatment.
- Mathematical formulation:

$$N(t) = N_0 e^{(r-\Delta r)t}$$

- Use: Useful for preliminary studies to assess the basic inhibitory effects of DHA on tumor proliferation.

Logistic growth model

The logistic growth model incorporates the carrying capacity K:

$$N(t) = \frac{N_0 K e^{rt}}{K + N_0 (e^{rt} - 1)}$$

Application with DHA:

- Effect on growth rate: DHA can reduce the growth rate rr, impacting how quickly the tumor reaches its carrying capacity.
- Effect on carrying capacity: DHA might also influence the carrying capacity KK by altering the tumor microenvironment.
- Mathematical formulation:
  $N(t) = N_0 K e^{(r-\Delta r)t} / K + N_0 \left(e^{(r-\Delta r)t} - 1\right)$
- Use: Suitable for modeling tumors in later stages where growth slows due to resource limitations.

Gompertz model

The Gompertz model captures the exponential decay in growth rate:

$$N(t) = N_0 K e^{((r-\Delta r)t)k} \left(1 - e^{-kt}\right)$$

Application with DHA:

- Effect on initial growth rate: DHA can reduce the initial growth rate rr.
- Effect on deceleration parameter: DHA might also affect the parameter bb, which determines the rate of deceleration.
- Mathematical formulation:
  $N(t) = N_0\ e(r-\Delta r)\,b(1-e-bt) N(t) = N_0\, eb(r-\Delta r)(1-e-bt)$
- Use: Ideal for modeling long-term tumor growth dynamics and the effectiveness of DHA over extended periods.

Key experimental considerations

In vitro studies:

- Cell proliferation assays: Measure the effects of various concentrations of DHA on tumor cell lines over time.
- Growth curves: Plot tumor size or cell count versus time to fit the appropriate growth model and determine parameters rr and ΔrΔr.

In vivo studies:

- Animal models: Administer DHA to tumor-bearing animals and monitor tumor growth to validate in vitro findings.
- Tumor size measurements: Regularly measure tumor volumes and fit the data to growth models to assess the impact of DHA.

Combination therapies:

- Synergistic effects: Study DHA in combination with other anti-cancer agents to evaluate potential synergistic effects on tumor growth inhibition.
- Modeling combination treatments: Extend growth models to include interactions between DHA and other treatments, potentially modifying both r and K.

Interpretation of results

- If Δr>0, DHA effectively reduces the initial growth rate of the tumor, suggesting it's potential as an anti-cancer agent.
- The parameter b should be monitored to see if DHA also affects the rate of deceleration of tumor growth.

Challenges and future directions

- Heterogeneity of tumor response: Tumors are heterogeneous, and the response to DHA can vary between different types and even within the same tumor.
- Dosage optimization: Determining the optimal dosage and administration schedule of DHA for maximum anti-tumor effect.
- Mechanistic insights: Integrating molecular and cellular mechanisms of DHA's action into growth models to enhance predictive power.
- Clinical translation: Bridging the gap between preclinical findings and clinical applications, ensuring that DHA's effects observed in models translate effectively to human patients.

Limitations and considerations

- Single parameter focus: The Gompertz model simplifies the complex dynamics of tumor growth and the multifaceted effects of DHA.
- In vitro vs. in vivo: Effects observed in cell cultures may differ in living organisms due to additional factors such as metabolism, immune response, and drug bioavailability.
- DHA dosage: The impact of different concentrations of DHA should be explored to determine the optimal therapeutic dose.

CONCLUSION

Mathematical models of tumor angiogenesis, whether continuous, discrete, or hybrid, provide valuable insights into the complex in-teractions between tumor cells, endothelial cells, and angiogenic factors. By incorporating various aspects of the angiogenic pro-cess, these models help in understanding tumor growth dynam- ics and developing targeted therapies to inhibit angiogenesis and tumor progression. Future research should focus on refining these models with experimental data and exploring their predictive capabilities in clinical settings. Incorporating DHA into tumor growth models, such as the exponential, logistic, and Gompertz models, allows researchers to quantitatively assess its anti-tumor effects and optimize therapeutic strategies. These models help in understanding the potential of DHA to slow tumor growth, im- prove patient outcomes, and develop effective cancer treatments. Future research should focus on refining these models, integrating mechanistic details, and validating findings through clinical trials.

REFERENCES

1. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Br J Clin Pharmacol. 2013;75:645-662.
2. Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in non-small cell lung cancer patients receiving chemotherapy. Cancer Res. 2011;71:797-807.
3. Rose DP, Connolly JM, Meschter CL. Effects of dietary fat on human breast cancer growth and lung metastasis in nude mice. J Natl Cancer Inst. 1991;83:1491-1495.
4. De Pillis LG, Radunskaya AE. Modeling tumor-immune dynamics. Math Comput Modell. 2003;37:1147-1165.
5. Benzekry S, Lamont C, Barbolosi D, Hlatky L, Hahnfeldt P, et al. Mathematical modeling of tumor growth and treatment. Math Model Nat Phenom. 2014;9:1-33.
6. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 1977;61:1307-1317.
7. Gompertz B. On the nature of the function expressive of the law of human mortality and on a new mode of determining the value of life contingencies. Philos Trans R Soc Lond. 1825;115:513-583.
8. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64:1094-1101.
9. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999;59:4770-4775.
10. Michor F, Iwasa Y, Nowak MA. Dynamics of cancer progression. Nat Rev Cancer. 2004;4:197-205.
11. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003;63:3847-3854.
12. Murray JD. Mathematical Biology II: Spatial Models and Biomedical Applications. Springer; 2003.
13. Laird AK. Dynamics of tumor growth. Br J Cancer. 1964;18:490-502.